Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: J Neurosurg. 2018 Dec 1;129(6):1397–1406. doi: 10.3171/2017.7.JNS171286

TABLE 4.

Incidence of local failure, hemorrhage, TRICs, and RN

Outcome No Ipilimumab (n = 91) Concurrent Ipilimumab (n = 59) Nonconcurrent Ipilimumab (n = 160) p Value
Local failure 17 (19%) 6 (10%) 30 (19%) 0.26
Lesion hemorrhage 13 (14%) 19 (32%) 24 (15%) 0.01
 Symptomatic 5 (5%) 3 (5%) 6 (4%) 0.76
TRIC 7 (8%) 8 (14%) 17 (11%) 0.50
 Symptomatic 0 (0%) 5 (8%) 9 (6%) 0.005
RN 0 (0%) 2 (3%) 3 (2%) 0.22

Values are shown as the number of lesions (%) unless otherwise indicated.